206 related articles for article (PubMed ID: 15651039)
41. Site specific gene delivery in the cardiovascular system.
Fishbein I; Stachelek SJ; Connolly JM; Wilensky RL; Alferiev I; Levy RJ
J Control Release; 2005 Dec; 109(1-3):37-48. PubMed ID: 16298010
[TBL] [Abstract][Full Text] [Related]
42. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.
Sondhi D; Peterson DA; Giannaris EL; Sanders CT; Mendez BS; De B; Rostkowski AB; Blanchard B; Bjugstad K; Sladek JR; Redmond DE; Leopold PL; Kaminsky SM; Hackett NR; Crystal RG
Gene Ther; 2005 Nov; 12(22):1618-32. PubMed ID: 16052206
[TBL] [Abstract][Full Text] [Related]
43. From leading role to the backstage: mesenchymal stem cells as packaging cell lines for in situ production of viral vectors.
Silva FH; Nardi NB
Med Hypotheses; 2006; 67(4):922-5. PubMed ID: 16737782
[TBL] [Abstract][Full Text] [Related]
44. Gene therapeutic approaches-transfer in vivo.
Evans CH; Gouze E; Gouze JN; Robbins PD; Ghivizzani SC
Adv Drug Deliv Rev; 2006 May; 58(2):243-58. PubMed ID: 16563557
[TBL] [Abstract][Full Text] [Related]
45. Current development of adeno-associated viral vectors.
Romano G
Drug News Perspect; 2005 Jun; 18(5):311-6. PubMed ID: 16193103
[TBL] [Abstract][Full Text] [Related]
46. Ribonucleic acid interference for neurological disorders: candidate diseases, potential targets, and current approaches.
Federici T; Boulis NM
Neurosurgery; 2007 Jan; 60(1):3-15; discussion 15-6. PubMed ID: 17228249
[TBL] [Abstract][Full Text] [Related]
47. Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw.
Spires TL; Hannan AJ
FEBS J; 2005 May; 272(10):2347-61. PubMed ID: 15885086
[TBL] [Abstract][Full Text] [Related]
48. Treating inflammation in childhood neurodegenerative disorders.
Lim M
Dev Med Child Neurol; 2011 Apr; 53(4):298-304. PubMed ID: 21309766
[TBL] [Abstract][Full Text] [Related]
49. Tailoring human embryonic stem cells for neurodegenerative disease therapy.
Sonntag KC; Sanchez-Pernaute R
Curr Opin Investig Drugs; 2006 Jul; 7(7):614-8. PubMed ID: 16869113
[TBL] [Abstract][Full Text] [Related]
50. Current status of polymeric gene delivery systems.
Park TG; Jeong JH; Kim SW
Adv Drug Deliv Rev; 2006 Jul; 58(4):467-86. PubMed ID: 16781003
[TBL] [Abstract][Full Text] [Related]
51. Prospects of treating neurological diseases by gene therapy.
Lundstrom K
Curr Opin Investig Drugs; 2007 Jan; 8(1):34-40. PubMed ID: 17263183
[TBL] [Abstract][Full Text] [Related]
52. Intra-peritoneal administration of genetic therapies: promises and pitfalls.
Evans TR; Keith WN
Minerva Ginecol; 2004 Dec; 56(6):529-38. PubMed ID: 15729205
[TBL] [Abstract][Full Text] [Related]
53. Viral and non-viral methods for gene transfer into skeletal muscle.
Wells DJ
Curr Opin Drug Discov Devel; 2006 Mar; 9(2):163-8. PubMed ID: 16566286
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic RNA interference for neurodegenerative diseases: From promise to progress.
Gonzalez-Alegre P
Pharmacol Ther; 2007 Apr; 114(1):34-55. PubMed ID: 17316816
[TBL] [Abstract][Full Text] [Related]
55. Toward development of artificial viruses for gene therapy: a comparative evaluation of viral and non-viral transfection.
Douglas KL
Biotechnol Prog; 2008; 24(4):871-83. PubMed ID: 18335953
[TBL] [Abstract][Full Text] [Related]
56. Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer.
Malik JM; Shevtsova Z; Bähr M; Kügler S
Mol Ther; 2005 Mar; 11(3):373-81. PubMed ID: 15727933
[TBL] [Abstract][Full Text] [Related]
57. [Gene and gene cellular therapy and neurodegenerative diseases].
Ugriumov MV; Ermakov AS; Popov AP; Zhdanov RI
Vopr Med Khim; 2000; 46(3):311-23. PubMed ID: 11033889
[TBL] [Abstract][Full Text] [Related]
58. Viral vectors as part of an integrated functional genomics program.
Janson CG; During MJ
Genomics; 2001 Nov; 78(1-2):3-6. PubMed ID: 11707065
[TBL] [Abstract][Full Text] [Related]
59. Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery.
Joshi CR; Labhasetwar V; Ghorpade A
J Neuroimmune Pharmacol; 2017 Mar; 12(1):51-83. PubMed ID: 28160121
[TBL] [Abstract][Full Text] [Related]
60. Gene therapy: Have the risks associated with viral vectors been solved?
Auman JT
Curr Opin Mol Ther; 2010 Dec; 12(6):637-8. PubMed ID: 21280375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
